A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in hiv-infected patients receiving rifampicin: The n2r study

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1752-1759

  Manosuthi, Weerawat ^a,b   Sungkanuparph, Somnuek ^b   Tantanathip, Preecha ^a   Lueangniyomkul, Aroon ^a   Mankatitham, Wiroj ^a   Prasithsirskul, Wisit ^a   Burapatarawong, Sunantha ^a   Thongyen, Supeda ^a   Likanonsakul, Sirirat ^a   Thawornwa, Unchana ^a   Prommool, Vilaiwan ^a   Ruxrungtham, Kiat ^c,d  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PLASMA; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; RNA, VIRAL; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 66949118251     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599114     Document Type: Article

References (34)

1. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV- infected individuals following initiation ofantiretroviral therapy. JAMA 1998; 279:450-4.
3. Putong N, Pitisuttithum P, Supanaranond W, et al. Mycobacterium tuberculosis infection among HIV/AIDS patients in Thailand: clinical manifestations and outcomes. Southeast Asian J Trop Med Public Health 2002;33:346-51.
4. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
5. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sung- kanuparph S. Survival rate and risk factors of mortality among HIV/ tuberculosis- coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:42-6.
6. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and ri- fabutin drug interactions: an update. Arch Intern Med 2002;162:985-92.
7. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 2008. Available at http://AIDSinfo.nih.gov. Accessed 1 December 2008.
8. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28:450-3.
9. Bartl ett GB, Gallant JE. 2007 Medical management of HIV infection. Baltimore, MD: Johns Hopkins Health Publishing Business Group, 2007.
10. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with an- tiretroviral therapy (2006). HIV Med 2006;7:487-503.
11. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment ofadult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
12. National Institute of Allergy and Infectious Disease. Division of AIDS table for grading the severity of adult and pediatric adverse events. December 2004. Available at: http://www.ucdmc.ucdavis.edu/clinicaltrials/ documents/DAIDS-AE-GradingTable-FinalDec2004.pdf.
13. Hollanders RM, van Ewijk-Beneken Kolmer EW, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevirapine, an HIV- 1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744:65-71.
14. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19:589-601.
15. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-302.
16. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006;20:
17. 131-2.
18. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008;13: 529-36.
19. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43:253-5.
20. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007;44:141-4.
21. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 ;15: 71-5.
22. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevi rapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-95.
23. Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med 2006; 7:323-30.
24. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007;21:1579-89.
25. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine- based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008;22:2117-25.
26. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Phamacol Ther 2000;68:401-11.
27. Kashuba AD. Drug-drug interactions and the pharmacotherapyofHIV infection. Top HIV Med 2005; 13:64-9.
28. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003; 34(Suppl 1):S8-14.
29. Joly V, Yeni P. Non-nucleoside reverse transcriptase inhibitors [in French]. Ann Med Interne (Paris) 2000; 151:260-7.
30. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-9.
31. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
32. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
33. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV- infected individuals. Clin Pharmacol Ther 2007; 81:557-66.
34. Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22:232-9.